Stocks and Investing
Stocks and Investing
Mon, December 19, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Chris Shibutani Initiated (VTYX) at Strong Buy and Held Target at $50 on, Dec 19th, 2022
Chris Shibutani of Goldman Sachs, Initiated "Ventyx Biosciences, Inc." (VTYX) at Strong Buy and Held Target at $50 on, Dec 19th, 2022.
Chris has made no other calls on VTYX in the last 4 months.
There are 4 other peers that have a rating on VTYX. Out of the 4 peers that are also analyzing VTYX, 0 agree with Chris's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Chris
- Simon Flannery of "Morgan Stanley" Initiated at Buy and Held Target at $45 on, Thursday, November 17th, 2022
- Alex Thompson of "Stifel" Maintained at Strong Buy with Increased Target to $53 on, Friday, September 16th, 2022
- Emily Bodnar of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $50 on, Tuesday, September 13th, 2022
- Jeff Jones of "Oppenheimer" Maintained at Buy with Increased Target to $65 on, Monday, September 12th, 2022
Contributing Sources